Atopic dermatitis is associated with a heterogeneous distribution of lesions and several distinct patterns of lesional distribution, which were associated with poorer quality of life.
Investigators sought to determine the effect dupilumab has on patch testing results and improvement of allergic contact dermatitis in patients with allergic dermatitis.
A group of councilors and associates of the International Eczema Council provide practice recommendations for the design and execution of placebo-controlled-trials with systemic medications for atopic dermatitis.
Investigators observed that conjunctivitis is more common with dupilumab treatment in clinical trials of patients with atopic dermatitis than trials in patients with asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis.
For all measures, worse child atopic dermatitis severity linked to worse maternal sleep outcomes
Dupilumab demonstrated similar efficacy to that seen in clinical trials, but higher rates of conjunctivitis and eosinophilia.
Two phase 1 studies assessed the safety, tolerability, and pharmacokinetics of tezepelumab with evidence of efficacy in asthma and potential therapeutic benefit in atopic dermatitis.
The study showed that both the nasal and skin microbiomes are associated with the severity of atopic dermatitis in children.
Data from 4 phase 3 trials suggest that all anatomic regions are equally responsive to dupilumab treatment in patients with moderate-to-severe atopic dermatitis.
The FDA has approved the use of Dupixent (dupilumab; Sanofi and Regeneron) to treat moderate-to-severe atopic dermatitis in adolescent patients 12–17 years old.